Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults

Xiaoqiang Liu, Yuhua Li, Zhongfang Wang, Shouchun Cao, Weijin Huang, Lin Yuan, Yi-Jiao Huang, Yan Zheng, Jingjing Chen, Bo Ying, Zuoyun Xiang, Jin Shi, Jincun Zhao, Zhen Huang, View ORCID ProfileCheng-Feng Qin
doi: https://doi.org/10.1101/2022.05.30.22275753
Xiaoqiang Liu
1Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhua Li
2National Institutes for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhongfang Wang
3Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shouchun Cao
2National Institutes for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weijin Huang
2National Institutes for Food and Drug Control, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Yuan
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Jiao Huang
5State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Zheng
1Yunnan Province Centre for Disease Control and Prevention, Kunming, Yunnan, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingjing Chen
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Ying
6Suzhou Abogen Biosciences Co., Ltd., Suzhou, Jiangsu, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zuoyun Xiang
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin Shi
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jincun Zhao
3Respiratory Medicine, Guangzhou Institute of Respiratory Health, Guangzhou, Guangdong, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: qincf{at}bmi.ac.cn hz{at}walvax.com zhaojincun{at}gird.cn
Zhen Huang
4Walvax Biotechnology Co., Ltd., Kunming, Yunnan China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: qincf{at}bmi.ac.cn hz{at}walvax.com zhaojincun{at}gird.cn
Cheng-Feng Qin
5State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China
7Research Unit of Discovery and Tracing of Natural Focus Diseases, Chinese Academy of Medical Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cheng-Feng Qin
  • For correspondence: qincf{at}bmi.ac.cn hz{at}walvax.com zhaojincun{at}gird.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Homologous and heterologous booster with COVID-19 mRNA vaccines represent the most effective strategy to prevent the ongoing Omicron pandemic. The additional protection from these prototype SARS-CoV-2 S-targeting vaccine was attributed to the increased RBD-specific memory B cells with expanded potency and breadth. Herein, we show the safety and immunogenicity of heterologous boosting with the RBD-targeting mRNA vaccine AWcorna (also term ARCoV) in Chinese adults who have received two doses inactivated vaccine. The superiority over inactivated vaccine in neutralization antibodies, as well as the safety profile, support the use of AWcorna as heterologous booster in China.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ChiCTR2100053701

Funding Statement

This work was supported in part by grant from the National Key Research and Development Program of China (2021YFC2302400) and the National Science Foundation of China (82151222). C.-F.Q. was supported by the National Science Fund for Distinguished Young Scholars (81925025), the Innovative Research Group (81621005) from the National Science Foundation of China and the Innovation Fund for Medical Sciences (2019-I2M-5-049) from the Chinese Academy of Medical Science.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Research Ethics Committee of the Center for Disease Control and Prevention of Yunnan province gave ethical approve for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 31, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu, Yuhua Li, Zhongfang Wang, Shouchun Cao, Weijin Huang, Lin Yuan, Yi-Jiao Huang, Yan Zheng, Jingjing Chen, Bo Ying, Zuoyun Xiang, Jin Shi, Jincun Zhao, Zhen Huang, Cheng-Feng Qin
medRxiv 2022.05.30.22275753; doi: https://doi.org/10.1101/2022.05.30.22275753
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu, Yuhua Li, Zhongfang Wang, Shouchun Cao, Weijin Huang, Lin Yuan, Yi-Jiao Huang, Yan Zheng, Jingjing Chen, Bo Ying, Zuoyun Xiang, Jin Shi, Jincun Zhao, Zhen Huang, Cheng-Feng Qin
medRxiv 2022.05.30.22275753; doi: https://doi.org/10.1101/2022.05.30.22275753

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)